Reported 3-year follow-up data from the Phase 1 AQUAx clinical study of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). 62% of participants reported at least a 10-point improvement in the Xerostomia Questionnaire (XQ) at 36 months, consistent with 12-month results. Unstimulated Whole Saliva Flow Rate (UWSFR) normalized to an average of 0.34 mL/min at 36 months, maintaining 12-month improvements. Treatment was safe and well-tolerated with no dose-limiting toxicity or treatment-related serious adverse events. Company estimates peak global annual revenue potential for AAV-hAQP1 at approximately $3.7 billion.